Dianthus Therapeutics Stock Forecast

Buy candidate since Jun 12, 2026

The Dianthus Therapeutics, Inc. stock price gained 7.35% on the last trading day (Friday, 12th Jun 2026), rising from $76.45 to $82.07. During the last trading day the stock fluctuated 8.35% from a day low at $77.16 to a day high of $83.61. The price has been going up and down for this period, and there has been a -11.76% loss for the last 2 weeks. Volume fell on the last day by -66 thousand shares and in total, 1 million shares were bought and sold for approximately $112.95 million. You should take into consideration that falling volume on higher prices causes divergence and may be an early warning about possible changes over the next couple of days.

The stock lies in the middle of a very wide and weak rising trend in the short term and a further rise within the trend is signaled. Given the current short-term trend, the stock is expected to rise 2.74% during the next 3 months and, with a 90% probability hold a price between $78.60 and $100.12 at the end of this 3-month period.

DNTH Signals & Forecast

There are mixed signals in the stock today. The Dianthus Therapeutics, Inc. stock holds a buy signal from the short-term Moving Average; at the same time, however, the long-term average holds a general sell signal. Since the longterm average is above the short-term average there is a general sell signal in the stock giving a more negative forecast for the stock. On further gains, the stock will meet resistance from the long-term Moving Average at $85.78. On a fall, the stock will find some support from the short-term average at $80.77. A break-up through the long-term average will give another buy signal, while a fall below the short-term average will add another sell signal and strengthen the general signal. Furthermore, there is currently a sell signal from the 3 month Moving Average Convergence Divergence (MACD). A buy signal was issued from a pivot bottom point on Wednesday, June 10, 2026, and so far it has risen 7.39%. Further rise is indicated until a new top pivot has been found. Volume fell during the last trading day despite gaining prices. This causes a divergence between volume and price and it may be an early warning. The stock should be watched closely.

Support, Risk & Stop-loss for Dianthus Therapeutics, Inc. stock

On the downside, the stock finds support just below today's level from accumulated volume at $77.86 and $77.76. There is a natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Dianthus Therapeutics, Inc. finds support just below today's level at $77.86. If this is broken, then the next support from accumulated volume will be at $77.76 and $76.42.

This stock has average movements during the day and with good trading volume, the risk is considered to be medium. During the last day, the stock moved $6.45 between high and low, or 8.35%. For the last week, the stock has had daily average volatility of 8.29%.

Our recommended stop-loss: $79.12 (-3.60%) (This stock has medium daily movements and this gives medium risk. There is a buy signal from a pivot bottom found 2 days ago.)

Trading Expectations (DNTH) For The Upcoming Trading Day Of Monday 15th

For the upcoming trading day on Monday, 15th we expect Dianthus Therapeutics, Inc. to open at $80.95, and during the day (based on 14 day Average True Range), to move between $79.20 and $84.94, which gives a possible trading interval of +/-$5.74 (+/-7.25%) up or down from last closing price. If Dianthus Therapeutics, Inc. takes out the full calculated possible swing range there will be an estimated 7.25% move between the lowest and the highest trading price during the day.

Since the stock is closer to the resistance from accumulated volume at $82.45 (0.46%) than the support at $77.86 (5.13%), our systems don't find the trading risk/reward intra-day attractive and any bets should be held until the stock is closer to the support level.

Is Dianthus Therapeutics, Inc. stock A Buy?

Several short-term signals, along with a general good trend, are positive and we conclude that the current level may hold a buying opportunity as there is a fair chance for Dianthus Therapeutics, Inc. stock to perform well in the short-term. We have upgraded our analysis conclusion for this stock since the last evaluation from a Sell to a Buy candidate.

Current score: 1.385 Buy Candidate Upgraded

Predicted Fair Opening Price

Predicted fair opening price on June 15, 2026 - $80.95 ( 1.37%).

Want to trade but not sure how? Our step-by-step guide can help.
Skip the guide? Open account with our trusted broker*
*Your capital is at risk